ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2010
Human epidermal growth factor receptor 2 testing: where are we?
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Refining the definition of HER2-low class in invasive breast cancer.Histopathology · 2022Article
- Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases.Journal of translational medicine · 2017Article
- In situ hybridization to detect and localize signature cytokines of T-helper (Th) 1 and Th2 immune responses in chicken tissues.Veterinary immunology and immunopathology · 2016Article
- Free digital image analysis software helps to resolve equivocal scores in HER2 immunohistochemistry.Virchows Archiv : an international journal of pathology · 2016Article
- The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831.Breast cancer research : BCR · 2015Article
- Comparative study between quantitative digital image analysis and fluorescence in situ hybridization of breast cancer equivocal human epidermal growth factor receptors 2 score 2(+) cases.Journal of pathology informatics · 2015Article
- Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.Journal of the National Cancer Institute · 2014Article
- Article
- Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).Breast cancer research and treatment · 2013Article
- HER2 Status by Standardized Immunohistochemistry and Silver-Enhanced In Situ Hybridization in Korean Breast Cancer.Journal of breast cancer · 2012Article
- Girdin protein: a new potential distant metastasis predictor of breast cancer.Medical oncology (Northwood, London, England) · 2012Article
- HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.Journal of translational medicine · 2012Article
- Female breast cancer status according to ER, PR and HER2 expression: a population based analysis.Pathology oncology research : POR · 2011Article
Corrections and comments
- Commented on by
- Comment on
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
20697080What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.